Critical Contrast: Liminal BioSciences (NASDAQ:LMNL) and Capricor Therapeutics (NASDAQ:CAPR)
Critical Contrast: Liminal BioSciences (NASDAQ:LMNL) and Capricor Therapeutics (NASDAQ:CAPR)
Liminal BioSciences (NASDAQ:LMNL – Get Rating) and Capricor Therapeutics (NASDAQ:CAPR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
利明生物科學(納斯達克：LMNL-GET Rating)和凱捷治療(納斯達克：CAPR-GET Rating)都是小盤醫療公司，但哪一項投資更具優勢？我們將根據這兩家公司的機構所有權、股息、收益、風險、估值、盈利能力和分析師的建議來比較它們的實力。
Valuation & Earnings
估值與收益
This table compares Liminal BioSciences and Capricor Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Limina BioSciences和Capricor Treeutics的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Liminal BioSciences | $510,000.00 | 29.83 | $10.28 million | $1.51 | 0.32 |
| Capricor Therapeutics | $250,000.00 | 577.49 | -$20.02 million | ($1.04) | -5.70 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 邊緣生物科學 | $510,000.00 | 29.83 | 1028萬美元 | $1.51 | 0.32 |
| 卡布裏卡治療公司 | $250,000.00 | 577.49 | -2,002萬元 | ($1.04) | -5.70 |
Liminal BioSciences has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Liminal BioSciences, indicating that it is currently the more affordable of the two stocks.
利明生物科學公司的收入和收益比Capricor Treateutics更高。Capricor Treateutics的市盈率低於Limina BioSciences，這表明它目前是兩隻股票中更負擔得起的一隻。
Risk & Volatility
風險與波動性
Insider & Institutional Ownership
內部人與機構所有權
0.9% of Liminal BioSciences shares are owned by institutional investors. Comparatively, 10.4% of Capricor Therapeutics shares are owned by institutional investors. 9.0% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Limina BioSciences 0.9%的股份由機構投資者持有。相比之下，Capricor Treateutics 10.4%的股份由機構投資者持有。Capricor Treateutics 9.0%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一隻股票的長期表現將好於大盤。
Profitability
盈利能力
This table compares Liminal BioSciences and Capricor Therapeutics' net margins, return on equity and return on assets.
此表比較了Limina BioSciences和Capricor Treeutics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Liminal BioSciences | 3,107.45% | -114.78% | -33.39% |
| Capricor Therapeutics | N/A | -89.89% | -48.31% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 邊緣生物科學 | 3,107.45% | -114.78% | -33.39% |
| 卡布裏卡治療公司 | 不適用 | -89.89% | -48.31% |
Analyst Recommendations
分析師建議
This is a breakdown of current ratings for Liminal BioSciences and Capricor Therapeutics, as reported by MarketBeat.
這是MarketBeat報道的Limina BioSciences和Capricor Treeutics目前的評級細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Liminal BioSciences | 0 | 0 | 0 | 0 | N/A |
| Capricor Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 邊緣生物科學 | 0 | 0 | 0 | 0 | 不適用 |
| 卡布裏卡治療公司 | 0 | 0 | 2 | 0 | 3.00 |
Capricor Therapeutics has a consensus target price of $15.00, indicating a potential upside of 152.95%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Liminal BioSciences.
Capricor Treateutics的共識目標價為15美元，表明潛在上漲152.95%。考慮到Capricor治療公司更高的可能上行空間，分析人士顯然認為Capricor治療公司比Limina生物科學公司更有利。
Summary
摘要
Capricor Therapeutics beats Liminal BioSciences on 7 of the 13 factors compared between the two stocks.
Capricor Treateutics在兩隻股票之間的13個因素中有7個擊敗了Limina BioSciences。
About Liminal BioSciences
關於利明生物科學
(Get Rating)
(獲取評級)
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
利姆納生物科學公司是一家臨牀階段的生物製藥公司，專注於在加拿大和英國開發治療炎症性、纖維化和代謝性疾病的新型小分子藥物療法。該公司的主要候選產品是非扎格普拉斯(PBI-4050)，它已經完成了第一階段的臨牀試驗，用於治療使用非扎格普拉斯或相關衍生物以及呼吸系統疾病的特發性肺、肝、心臟或皮膚纖維化。該公司還在開發候選拮抗劑項目，包括處於臨牀前階段的G蛋白偶聯受體84和氧代二十烷類受體1。該公司前身為ProMtic Life Science Inc.，並於2019年10月更名為Limina BioSciences Inc.。利姆納生物科學公司成立於1994年，總部設在加拿大拉瓦爾。
About Capricor Therapeutics
關於Capricor Treateutics
(Get Rating)
(獲取評級)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
卡布里科治療公司(納斯達克代碼：CAPR)是一家臨牀階段的生物技術公司，專注於治療罕見疾病的一流生物療法的發現、開發和商業化。Capricor的主要候選藥物CAP-1002是一種異基因細胞療法，目前正在臨牀開發中，用於治療Duchenne肌營養不良症。Capricor還確立了自己作為研究細胞外小泡領域的領先公司之一的地位，並正在探索CAP-2003的潛力，CAP-2003是一種基於外切體的無細胞候選藥物，用於治療各種疾病。
Receive News & Ratings for Liminal BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminal BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《利明生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Limina BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。